Chronic Kidney Disease Market to Witness Promising Upswing by 2034, DelveInsight Forecasts

The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.

DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Kidney Disease Market Report:
• The Chronic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In Sept 2025, eGenesis obtained FDA approval for its Investigational New Drug (IND) application to initiate clinical trials of EGEN-2784, a genetically engineered porcine kidney, for end-stage kidney disease (ESKD). The Phase 1/2/3 trial will assess safety and efficacy in dialysis-dependent patients aged 50 and above who are on the transplant waiting list.
• In August 2025, Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotech company specializing in kidney disease therapies, announced that the U.S. Patent and Trademark Office has issued U.S. Patent 12,377,082 for UNI-494 in the treatment of Chronic Kidney Disease (CKD). This patent extends a prior method-of-use patent that covered UNI-494 for treating Acute Kidney Injury.
• In March 2025, The FDA approved an expanded indication for furosemide injection (Furoscix; scPharmaceuticals, Inc.) to manage edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome. The expanded treatment is anticipated to be available by April 2025, following the FDA's acceptance of the supplemental new drug application in July 2024.
• In February 2025, Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company leveraging human genetics to develop innovative small-molecule precision medicines for renal, cardiovascular, and metabolic diseases, has announced that the first patient has been dosed in its Phase 2 HORIZON Study of MZE829 for APOL1 kidney disease (AKD). MZE829 is an oral small-molecule APOL1 inhibitor being developed as a potential treatment for AKD, a form of chronic kidney disease that affects over one million patients in the United States.
• In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a target action date of June 28, 2025, under the PDUFA. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in Chronic Kidney Disease patients undergoing dialysis.
• In July 2024, Renalys Pharma has raised ¥6 billion ($3.8 million) in a Series A funding round to advance clinical trials for kidney disease treatments across Asia. The financing was led by Catalys Pacific and SR One, with additional support from a group of investors, including JPS Growth Investment Limited Partnership, Sumitomo Mitsui Trust Bank, Japan Co-Invest IV Limited Partnership, and NVCC No.9 Investment Limited Partnership.
• The Chronic Kidney Disease therapeutics market size in the US was approximately USD 2,824 million in 2023 and is expected to grow further during the forecast period.
• In 2023, the United Kingdom had the largest Chronic Kidney Disease market size among the EU countries, with nearly USD 421 million, while Italy recorded the smallest market size at approximately USD 132 million.
• The Chronic Kidney Disease therapeutics market size in Japan was estimated at around USD 1,402 million in 2023.
• According to DelveInsight's analysis, the total diagnosed prevalent cases of Chronic Kidney Disease in the 7MM were approximately 16 million in 2023.
• In 2023, the United States held the largest Chronic Kidney Disease market size among the 7MM, valued at around USD 2,824 million, with projections indicating further growth by 2034.
• In 2023, the United States reported the highest prevalence of Chronic Kidney Disease among the 7MM, with approximately 40 million cases, and this number is projected to grow by 2034.
• The Chronic Kidney Disease market in 2023, valued at USD 5,479 million across the 7MM, primarily consists of erythropoietin-stimulating agents (ESAs), ACE inhibitors, angiotensin receptor blockers (ARBs), antidiabetic medications, treatments for secondary hyperparathyroidism (SHPT), and urate-lowering therapies. The market is anticipated to expand further with the introduction of emerging therapies during the forecast period (2024-2034).
• In 2023, Japan's Chronic Kidney Disease market size was valued at USD 1,402 million, with projections indicating substantial growth at a notable CAGR by 2034.
• In 2023, the United Kingdom had the highest number of diagnosed prevalent cases of Chronic Kidney Disease among European countries, with around 2 million cases, followed by Germany with approximately 1 million cases. Italy, on the other hand, had the lowest prevalent population, totaling 731 thousand cases.
• In 2023, Japan reported nearly 3 million total diagnosed prevalent cases of Chronic Kidney Disease, representing about 22% of the total cases across the 7MM.
• DelveInsight's analysis shows that in the EU4 and the UK, more females are impacted than males, with approximately 3.55 million female cases and 3.4 million male cases in 2023.
• Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others
• Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others
• The Chronic Kidney Disease epidemiology based on gender analyzed that Chronic Kidney Disease is slightly more common in women (14%) than men (12%)

Chronic Kidney Disease Overview
Chronic Kidney Disease (CKD) is a long-term condition characterized by a gradual loss of kidney function over time. The kidneys play a crucial role in filtering waste, toxins, and excess fluids from the blood. In CKD, this filtering ability is impaired, leading to a buildup of harmful substances in the body.
The condition is often caused by underlying health issues such as diabetes, high blood pressure, or glomerulonephritis. Symptoms may not appear until the disease is advanced and can include fatigue, swelling, nausea, and difficulty concentrating. Left untreated, CKD can progress to kidney failure, requiring dialysis or a kidney transplant. Early detection and management, including lifestyle changes and medications, can help slow disease progression.

Get a Free sample for the Chronic Kidney Disease Market Report:
https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Kidney Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Kidney Disease
• Prevalent Cases of Chronic Kidney Disease by severity
• Gender-specific Prevalence of Chronic Kidney Disease
• Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Kidney Disease
• Prevalent Cases of Chronic Kidney Disease by severity
• Gender-specific Prevalence of Chronic Kidney Disease
• Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

Chronic Kidney Disease Market
The dynamics of the Chronic Kidney Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"Although the pipeline for the treatment of Chronic Kidney Disease looks robust, most of the investigational therapies aim at improving kidney function (measured by improved renal output), there are no curative therapies in development that aim to regain kidney function."

Chronic Kidney Disease Therapies and Key Companies
• TRC101 (Veverimer): Tricida
• Tolvaptan: Otsuka Pharmaceuticals
• AZD5718: AstraZeneca

To know more about Chronic Kidney Disease treatment, visit @ Chronic Kidney Disease Medications
https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Kidney Disease Market Drivers
• Rising Prevalence of CKD
• Advancements in Diagnostic Tools
• Development of Novel Therapies
• Increased Healthcare Spending
• Awareness Campaigns
• Favorable Regulatory Approvals

Chronic Kidney Disease Market Barriers
• High Treatment Costs
• Limited Access to Healthcare
• Late Diagnosis
• Side Effects of Therapies
• Regulatory Hurdles
• Patient Adherence Issues

Scope of the Chronic Kidney Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others
• Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others
• Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies
• Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Chronic Kidney Disease Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.